Advertisement

Topics

FDA Approves Erdafitinib for Advanced Bladder Cancer

07:57 EDT 16 Apr 2019 | NEJM

Erdafitinib (marketed as Balversa) has been approved to treat adults with locally advanced or metastatic bladder cancer who carry fibroblast growth factor receptor (FGFR) alterations...

Original Article: FDA Approves Erdafitinib for Advanced Bladder Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Erdafitinib for Advanced Bladder Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...